Glucotrack appoints Andy Balo (ex-Dexcom EVP) to board; bylaws amended to lower quorum to one-third

Glucotrack, Inc.

Appointed Andrew K. Balo, former Dexcom EVP of Clinical & Global Access, to board as independent director, effective June 14, 2024.
Balo brings 22 years at Dexcom, expertise in glucose monitoring regulatory submissions and clinical trials.
Board also amended bylaws to reduce shareholder quorum requirement from majority to one-third.
Balo will assist with upcoming human clinical studies for Glucotrack's implantable continuous blood glucose monitor.
Balo played critical role at Dexcom; his regulatory knowledge expected to aid Glucotrack's CBGM development.

item 5.02 item 5.03 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew K. Balo

independent board member

GCTK · Glucotrack, Inc.

Effective: 2024-06-14
Filed: June 20, 2024, 7:59 PM ET

On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Andrew K. Balo was appointed as independent board member at Glucotrack, Inc..

Action: appointed
Role: independent board member

Exact text from the filing

On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.

View on SEC.gov

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-024427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.